Compare Abeona Therapeutics Inc (ABEO) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Invesco S&P 500 Low Volatility ETF trades at $76.12. Which is the better fit depends on your goals.
| ABEO | SPLV | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $77.45 |
52-Week Low | $4.17 | $70.30 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SPLV trades at $76.17, down 0.73% today, maintaining a bullish technical outlook with strong moving average support. The ETF focuses on low-volatility S&P 500 stocks, offering defensive exposure during market uncertainty. Recent news highlights its role in portfolio diversification amid tech sector volatility, with institutional investors showing mixed positioning.
The outlook remains positive for risk-averse investors seeking stable equity exposure. Key risks include potential underperformance during strong bull markets and concentration in defensive sectors. Analyst sentiment is generally favorable for defensive portfolio allocation, though specific financial metrics for the ETF are not publicly detailed like individual stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
